Skip to main content
. 2020 Feb 27;10(10):1943–1953. doi: 10.1016/j.apsb.2020.02.010

Figure 2.

Figure 2

Design of IDO1 PROTAC degraders. (A) The co-crystal structure of IDO1 (green, PDB: 5WN8) and CRBN (pink, PDB: 5FQD) with their ligand Epa and lenalidomide respectively. Linker was attached via the solvent exposed site. (B) Structure of IDO1 PROTACs based on Epa and CRBN ligands.